Breast Clinical Trials

USOR #20408

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor – Positive HER2-Negative Early Breast Cancer (GO42784)